EFFECTIVENESS OF CLINICAL PARAMETERS AND LABORATORY VALUES IN PREDICTING THE CLINICAL COURSE OF SARCOIDOSIS-SINGLE CENTER EXPERIENCE
Author:
ÇELİK Deniz,BULUT Sertan
Publisher
Acta Medica Alanya
Reference25 articles.
1. 1. Rahaghi FF, Baughman RP, Saketkoo LA, Sweiss NJ, Barney JB, Birring SS, et al. Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev. 2020 Mar 20;29(155):190146. doi: 10.1183/16000617.0146-2019. PMID: 32198218.
2. 2. Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, et al. ACCESS Research Group. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004 Dec 15;170(12):1324-30. doi: 10.1164/rccm.200402-249OC. Epub 2004 Sep 3. PMID: 15347561.
3. 3. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999 Aug;160(2):736-55. doi: 10.1164/ajrccm.160.2.ats4-99. PMID: 10430755.
4. 4. Scadding JG. Sarcoidosis, with Special Reference to Lung Changes. Br Med J. 1950 Apr 1;1(4656):745-53. doi: 10.1136/bmj.1.4656.745. PMID: 20787829; PMCID: PMC2037093.
5. 5. Aykan, F. S., Türktaş H., Köktürk N., Akten, S. Y. Retrospective Evaluation of 100 Patients with Sarcoidosis in Gazi University, Turkey. Turk Thorac J 2014; 15: 155-161 DOI: 10.5152/ttd.2014.4116 (no PMID)